Collection of tumor samples and liquid biopsies
tumor, Tumor
DISEASE PROGRESSION, TUMOR, TUMOR, DISEASE, EVENT
Prior to first-line immunotherapy, tumor biopsy will be performed as part of standard care for patients with histologically proven disease. Tumor biopsies will be performed prior to second-line immunotherapy following chemotherapy and 3 months (D84 ± 5 days) after the start of treatment. Biopsies will be proposed only if disease progression is observed and 50 days after the start of chemotherapy following immunotherapy. Samples will be processed using the standard formalin-fixed paraffin-embedded (FFPE) procedure.Liquid biopsies will be taken before the start of anti-PD-1 immunotherapy, before and after each of the 4 cycles (20-day cycle) up to 84 days (± 4 days) after the start of immunotherapy, and finally at the end of anti-PD-1 immunotherapy (10 samples per patient). Biopsies will also be performed in the event of disease progression prior to the initiation of a new line of chemotherapy. Liquid biopsies will be collected in anti-coagulant ethylenediaminetetraacetic acid (EDTA)-treated RNA Complete blood collection tubes (BCT). Cell-free plasma samples will be isolated by a two-step centrifugation (1,200 g, 10 min and 16,000 g, 10 min) and aliquoted before storage at -80 °C in the Biobank of the UNICANCER Centre Paul Strauss in Strasbourg.